Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC

AIDS

Volumn 10, Issue 14, 1996, Pages

  Ruiz, Lidia ^a   Romeu, Joan ^b   Martínez Picado, Javier ^a   Schmit, Jean Claude ^c   Vandamme, Anne Mieke ^c   Balagué, Montserrat ^b   Cabrera, Cecilia ^a   Puig, Teresa ^a   Tural, Cristina ^b   Segura, Antònia ^b   Sirera, Guillem ^b   De Clercq, Erik ^c   Clotet, Bonaventura ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiretroviral therapy; Lamivudine; Triple combination therapy; Viral load; Zalcitabine; Zidovudine

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 10544249459     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199612000-00003     Document Type: Article

References (17)

1. 3. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract LB-1].
2. Katzenstein D, Hammer S, Hughes M, et al.: Plasma virion RNA in response to early antiretroviral drug therapy in ACTG 175. Do changes in virus load parallel clinical and immunological outcomes? 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract LB-2].
3. Yeni P, International Coordinating Committee: Preliminary results of the European/Australian Delta trial based on data up to 31st May, 1995. 5th European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen, September 1995 [abstract LB-2].
4. Coates JAV, Cammach N, Jenkinson HJ, et al.: (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992, 36:733-739.
5. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-1-positive patients with 200 to 500 CD4+cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
6. Staszewski S, Miller V, Rehmet S, et al.: Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1 -infected patients. AIDS 1996, 10:F1-F7.
7. Carpenter ChCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. JAMA 1996, 276:146-154.
8. Mulder J, McKinney N, Christopherson C, et al.: Rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma: applications to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
9. Schmit JC, Cogniaux J, Hermans P, et al.: Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. J Infect Dis 1996 (in press).
10. Harrigan PR, Bloor S, Kinghorn I, et al.: Virological response to ZDV/3TC combination therapy in ZDV experienced patients (Trial NUCB 3002). 4th International Workshop on HIV Drug Resistance. Sardinia. July 1995 [abstract 54] .
11. Saag MS, Holodniy M, Kuritzkes DR, et al.: HIV viral load markers in clinical practice. Nature Med 1996, 2: 625-629.
12. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334: 426-431.
13. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
14. 3). 4th International Workshop on HIV Drug-Resistance. Sardinia, July 1995 [abstract 55].
15. Bartlett J, Benoit S, Sepulveda G, et al.: A randomized, doubleblind multicenter combination trial of lamivudine (3TC)/zidovudine (ZDV) combination therapy vs. ZDV/dideoxycytidine (ddC) combination therapy in ZDV experienced patients CD4+ 100-300/mm3. 2nd National Conference on Human Retroviruses. Washington, DC, January 1995 [abstract LB35].
16. Tisdale M, Kemp SD, Parry NR, et al.: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
17. Goulden MG, Cammack N, Hopewell PL, Penn CR, Cameron JM: Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine [letter]. AIDS 1996, 10:101-102.